5 completed, 1 recruiting. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Valsartan 160 mg: new trials by email Literature Review of Valsartan 160 mg trials Research Report on Valsartan 160 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 75 mg placebo, QR12000 Compound Tablets 150 mg - Essential Hypertension | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 391 | 2022-12-29 | 2026-07-14 |
| NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test - Diabetes Mellitus, Cardiovascular Diseases | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2020-08-15 | 2026-07-28 |
| Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Valsartan/amlodipine 160/5 mg, Valsartan 160 mg, Placebo - Essential Hypertension | Phase 3 | Completed | Novartis | 932 | 2009-09-01 | 2011-05-24 |
| Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg - Hypertension | Phase 3 | Completed | Novartis Pharmaceuticals | 1134 | 2007-01-01 | 2011-04-28 |
| Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker high sodium diet, low sodium diet, ramipril 10 mg - Healthy | Phase 1 | Completed | Assistance Publique - Hôpitaux de Paris | 64 | 2006-03-01 | 2008-09-22 |
| A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure valsartan 160 mg, valsartan 160 mg BID - Chronic Heart Failure | Phase 2 | Completed | Novartis | 160 | 2005-12-01 | 2011-06-08 |
Essential Hypertension (2) · Hypertension (2) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Insulin Resistance (1) · Metabolic Diseases (1)
Novartis (2) · Assistance Publique - Hôpitaux de Paris (1) · Novartis Pharmaceuticals (1) · University of Alabama at Birmingham (1) · Wuhan Createrna Science and Technology Co., Ltd (1)
China (2) · United States (2) · France (1)
Michel Azizi, MD, PhD (1) · Pankaj Arora, MD, FAHA (1)
PMID 20730060, PMID 25595796, PMID 27542885, PMID 28330649, PMID 31162140
R01HL163852 (1)